Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial

Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021

(2021) Summer E. Galloway et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome

(2021) Koichiro Suemori et al.   PLoS Neglected Tropical Diseases

Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients

(2021) Satoshi Fujii et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

(2021) Sandile Cele et al.   NATURE

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

(2020) Calvin J. Gordon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(2020) Fei Zhou et al.   LANCET

Virological assessment of hospitalized patients with COVID-2019

(2020) Roman Wölfel et al.   NATURE

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

(2020) Thomas J. Oxley et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

(2020) Qianqian Li et al.   CELL

A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19

(2020) Yohei Doi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity

(2020) Suzanne J. F. Kaptein et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis

(2020) Ashleigh Shannon et al.   Nature Communications

Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment

(2020) Yan Wang et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Clinical Features of 154 COVID-19 Patients and the Parameters for the Effective Detection of Pneumonia at the Time of the Initial Diagnosis in Japan

(2020) Miwa Morikawa et al.   INTERNAL MEDICINE

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

(2020) Zarir F. Udwadia et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Effective Oral Favipiravir (T-705) Therapy Initiated after the Onset of Clinical Disease in a Model of Arenavirus Hemorrhagic Fever

(2011) Michelle Mendenhall et al.   PLoS Neglected Tropical Diseases